Botanix is a dermatology company developing novel treatments for common skin diseases and infections
Botanix Pharmaceuticals is a dermatology company developing novel treatments for common skin diseases and infections.
27/07/2025
🔸 Botanix Releases Quarterly Reports 🔸
Quarterly Reports for Q4 FY2025 have been released. During the quarter, Botanix raised A$40m in capital, established a loan facility of up to the euro equivalent of US$30 million, and had A$64.9m cash on 30 June. With operating costs stable and revenues expected to rise, Botanix is well funded to support Sofdra™ (sofpironium) to profitability.
📆 28 July Quarterly Update Webinar – Registration Open
Join our executive team for the Company’s Quarterly Activity Report and 4c Cash Flow Webinar on Monday 28 July 9:00 am AEST / 7:00 am AWST for an important update.
📆 8 July Commercial Day Webinar – Registration Open
Join our executive team for the Company’s Sofdra™ Launch Update Webinar on Tuesday 8 July 9:30am AEST / 7:30am AWST to receive a comprehensive look at the strong initial demand and performance of Sofdra™.
is pleased to share that an article featuring sofpironium topical gel, 12.45% (Sofdra) appears in the July 2025 issue of the peer-reviewed Journal of the American Academy of Dermatology. The article presents pooled efficacy and safety results from 2 phase 3 randomized, controlled, double-blind studies that formed the basis for US Food and Drug Administration approval of Sofdra.
is pleased to have been featured in Dr Boreham’s Crucible, a column focusing on the Australian biotechnology and healthcare sectors. The interview with CEO, Dr Howie McKibbon includes in-depth look at Botanix and its fulfilment platform, commercialization strategies, and an update on the launch of Sofdra™ (sofpironium) gel, 12.45% in the US.
🔸 Botanix signs debt facility with Kreos Capital 🔸
has entered into documentation with Kreos Capital for a loan facility of up to US$30 million (~A$48 million).
Kreos Capital is a leading provider of growth and venture debt financing to companies in the technology and healthcare industries. The new debt facility will be available to Botanix for working capital purposes for the commercialisation of Sofdra™, as well as other platform expansion opportunities. H.C. Wainwright & Co. acted as origination, structuring and placement agent for the transaction.
“We are pleased to work with Kreos Capital in relation to the Facility, and appreciate the opportunity to do business with one of the world’s leading debt providers with more than 25 years of experience.
“The flexibility provided by the Facility will allow us to make rapid decisions to support the acceleration of Sofdra sales and move quickly to expand the platform as opportunities present themselves over the coming year.”
is pleased to share the latest Euroz Hartleys analyst report on Botanix, maintaining a price target of $0.80.
The report addresses President Trump's recent executive order on drug pricing and concludes it will have "little to no impact" on BOT or Sofdra™.
Euroz Hartleys Research Analyst, Seth Lizee, wrote:
“Sofdra is only approved and sold in the United States, so there is no lower international price to reference…Since Sofdra isn't available internationally, importing from lower-priced regions doesn’t apply.”
📆 Investor Webinar | Tuesday 15 April at 11.00am AEST
Botanix is pleased to invite investors to join an important company update presented by our leadership team, including Executive Chairman Vince Ippolito, Executive Director Matthew Callahan, and CEO Dr. Howie McKibbon.
When: Tuesday 15 April at 11am AEST / 9am AWST
Registration: Participants are required to register in advance for this webinar.
While in Australia this week, Botanix CEO Howie McKibbon spoke with Stockhead’s Tylah Tully about Botanix’s elevation to the S&P/ASX 300 index, and the Company’s ambitions to become a global leader in dermatology innovation.
Here’s an excerpt:
“It's a great honour and validation to join this league and a validation of the work that we've done and of our growth as a company. We’ll continue to focus on building Botanix to become the world’s largest and most innovative dermatology company.”
This is "Long Shortz: Botanix Pharmaceuticals (ASX:BOT)" by Stockhead on Vimeo, the home for high quality videos and the people who love them.
16/03/2025
đź“ş Interview with Howie McKibbon
CEO Howie McKibbon joined Sharecafe’s Abbey Phillipps this week to provide an update on the Company's recent US launch of Sofdra™ and commercial progress.
Howie shared insights on Botanix’s experienced sales team, momentum in securing contracts with payer organizations covering over 90% of commercially insured lives plus Medicaid coverage, and early results from a digital marketing campaign that's driving awareness and converting online interest into prescriptions.
"Our strategy is really for continuity of care and adherence. We want to make sure that once a physician or dermatologist has made the decision to prescribe Sofdra that the patient gets the product and gets it in the time period for which they're supposed to be using the product."
This week, Executive Director Matt Callahan spoke with ShareCafe’s Abbey Phillipps to discuss the Company’s recent US launch of Sofdra™.
Matt noted that early prescription growth is tracking to expectations only six weeks into the launch, and highlighting Botanix's unique platform that improves patient refill rates while enhancing profitability.
"Our platform is really a combination of the way in which we get products to patients and help them with their refills for continuity of care, and then separately, how we improve the profitability of our business by avoiding a lot of the fees, like distributor fees that often pull away from that profitability."
is pleased to announce that the Company will be included in the S&P/ASX 300 Index at the March rebalance.
The S&P/ASX 300, or simply, ASX 300, is a stock market index of Australian stocks listed on the Australian Securities Exchange (ASX). The ASX 300 index covers the large-cap, mid-cap, and small-cap components of the S&P/ASX Index Series.
To be considered for inclusion, a company must meet a minimum market capitalization, typically around A$100 million, based on average daily market cap over the last six months, and have sufficient liquidity; meaning the stock must be actively traded in adequate volume to be considered institutionally investable. The index is regularly reviewed, and companies are added or removed to rebalance twice annually reflecting changes in market capitalization and liquidity.
Be the first to know and let us send you an email when Botanix Pharmaceuticals posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
Botanix Pharmaceuticals Limited (ASX:BOT) is a clinical stage medical dermatology company based in Perth, Australia and Philadelphia, PA. The Company’s focus is the development of safe and effective topical treatments for acne, psoriasis, atopic dermatitis and other skin conditions. The active ingredient contained in Botanix products is a synthetic form of a widely studied natural compound. Treatment targets include inflammation, deterioration of the of the skin barrier, skin cell proliferation, pruritus (itch), excess sebum production and bacterial infection.
Botanix has an exclusive license to use a proprietary drug delivery system (PermetrexTM) for direct skin delivery of active pharmaceuticals in all skin diseases. Botanix is working with multiple parties to test the application of PermetrexTM on both a fee-for-service and traditional license basis.
Botanix pursues a rapid clinical development strategy aimed at accelerating product commercialisation. The patient treatment duration of clinical studies is generally completed within a 4 to 12-week timeframe.
The Company completed its first acne patient studies with BTX 1503 in January 2018 and has commenced a Phase 2 clinical trial in June 2018 with completion expected in mid-2019. The Phase 1b BTX 1204 atopic dermatitis patient study concluded in June 2018 and preparation is underway for a Phase 2 clinical trial. The Phase 1b BTX 1308 psoriasis patient study is due to commence in 4Q 2018.
